Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
13/11/2024 15:26
* Mersana Therapeutics Inc MRSN.OQ reported a quarterly
adjusted
loss of 9 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -27 cents. The mean expectation of
nine analysts for the quarter was for a loss of 18 cents per
share. Wall Street expected results to range from -23 cents
to -13 cents per share.
* Revenue rose 63.7% to $12.60 million from a year ago;
analysts
expected $7.53 million.
* Mersana Therapeutics Inc's reported EPS for the quarter
was a
loss of 9 cents.
* The company reported a quarterly loss of $11.5 million.
* Mersana Therapeutics Inc shares had risen by 16.4% this
quarter and lost 5.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 8.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Mersana
Therapeutics Inc is 7.00
This summary was machine generated from LSEG data November 13 at
03:25 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.18 -0.09 Beat
Jun. 30 2024 -0.17 -0.20 Missed
Mar. 31 2024 -0.18 -0.16 Beat
Dec. 31 2023 -0.16 -0.16 Met